MIRACIL. CLINICAL TRIAL ON PATIENTS INFECTED WITH SCHISTOSOMA HAEMATOBIUM AND S. MANSONI

Abstract

A previous paper (Hawking and Ross, 1948) Organization of therapeutic trialThe present investigation was carried out at Salisbury, Southern Rhodesia, beginning in the second half of 1947. Patients with active schistosome infections were selected for the trials. Urines and stools were collected and examined for the presence of eggs and miracidia. The urines were examined by collecting the terminal specimen of urine, centrifuging it, and examining the resultant deposit for eggs. Originally the faeces were examined by collecting material from the outer layers of the stool together with any blood or mucus present and making an emulsion, with pond water, in a 3-in. x 1-in. tube. This emulsion was then filtered through a coffee strainer and transfered to a conical urine glass, further pond water was added, and the whole was allowed to settle. The supernatant was poured off, fresh water was added, and this washing process was repeated several times. Finally the resultant deposit was examined 'microscopically for the presence of eggs. Later, improved methods of diagnosis were used both for urine and faeces, depending on the hatching out of miracidia from the washed deposit and their identification with a hand-lens under indirect illumination (Gorman, Meeser, Ross, and Blair, 1947;Meeser, Ross, and Blair, 1948). Most of the therapeutic trials were made on young patients who were passing eggs in large numbers; infections in adults are less satisfactory for this purpose, since excretion of eggs is often intermittent.Previous to treatment each patient was examined clinically and weighed stripped. The age in Africans can be ascertained only approximately. Before commencing treatment a haemoglobin estimation was

Lucanthone Targets Lysosomes to Perturb Glioma Proliferation, Chemoresistance and Stemness, and Slows Tumor Growth In Vivo

“…Lucanthone (marketed as Miracil D) is an anti-schistosome agent ( 15 – 20 ). It inhibits topoisomerase II and AP endonuclease 1 (APE1) ( 21 – 24 ).…”